Content about Behring

September 3, 2013

The Food and Drug Administration has approved a new vial size for a treatment for a rare immune system disorder.

KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a treatment for a rare immune system disorder.

CSL Behring announced the approval of a 10-g, or 50-mL, vial size for Hizentra (immune globulin subcutaneous [human]). The product is used to prevent infections in patients with primary immunodeficiency, and the new vial size will be available in October.

February 21, 2013

The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said.

KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said Thursday.